Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35167655

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Apr 14
First author
Frigault MJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Apr 14;139(15):2261-2263. doi: 10.1182/blood.2022015802.
    note
    Source null
    related pmid
    35420689
    relationship
    Comment in

Authors and identifiers

  1. name
    Frigault MJ
    type
    Author
  2. name
    Dietrich J
    type
    Author
  3. name
    Gallagher K
    type
    Author
  4. name
    Roschewski M
    type
    Author
  5. name
    Jordan JT
    type
    Author
  6. name
    Forst D
    type
    Author
  7. name
    Plotkin SR
    type
    Author
  8. name
    Cook D
    type
    Author
  9. name
    Casey KS
    type
    Author
  10. name
    Lindell KA
    type
    Author
  11. name
    Depinho GD
    type
    Author
  12. name
    Katsis K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Frigault MJ
    type
    Author
  2. name
    Dietrich J
    type
    Author
  3. name
    Gallagher K
    type
    Author
  4. name
    Roschewski M
    type
    Author
  5. name
    Jordan JT
    type
    Author
  6. name
    Forst D
    type
    Author
  7. name
    Plotkin SR
    type
    Author
  8. name
    Cook D
    type
    Author
  9. name
    Casey KS
    type
    Author
  10. name
    Lindell KA
    type
    Author
  11. name
    Depinho GD
    type
    Author
  12. name
    Katsis K
    type
    Author
bibliography ids
  1. nci-bib-83de782529c022efe13d9cde
book metadata
content sha256
cd7b939149610c4298c04316a3875fa1156cb5c5305dd62ee04a9cd0aab08245
document type
citation
dois
  1. 10.1182/blood.2021014738
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35167655
immutable id
pubmed:35167655@cd7b939149610c4298c04316a3875fa1156cb5c5305dd62ee04a9cd0aab08245
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
15
name
Blood
nlm unique id
7603509
pages
2306-2315
volume
139
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Apr 14;139(15):2261-2263. doi: 10.1182/blood.2022015802.
    note
    Source null
    related pmid
    35420689
    relationship
    Comment in
outcomes validated
false
pmid
35167655
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
317dd2f560bdbe0c4255a901e9802ca14e1ae4a0a158e66ec414a717673fa064
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Apr 14
precision
day
year
2022
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35167655/
title
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.

Preserved source evidence · Not medical advice